IVIG – A cure to severe refractory NAP-1 Clostridium difficile colitis? A case of successful treatment of severe infection, which failed standard therapy including fecal microbiota transplants and fidaxomicin

Kelley Coffman; Xian Jie Cindy Chen; Charles Okamura; Eddie Louie

doi:10.1016/j.idcr.2017.03.002

IDCases (Jan 2017)

IVIG – A cure to severe refractory NAP-1 Clostridium difficile colitis? A case of successful treatment of severe infection, which failed standard therapy including fecal microbiota transplants and fidaxomicin

Kelley Coffman,
Xian Jie Cindy Chen,
Charles Okamura,
Eddie Louie

Affiliations

Kelley Coffman: Department of Medicine, NYU Langone Medical Center, New York, NY, USA
Xian Jie Cindy Chen: Department of Pharmacy, NYU Langone Medical Center, New York, NY, USA
Charles Okamura: Department of Medicine, NYU Lutheran Medical Center, Brooklyn, NY, USA
Eddie Louie: Department of Medicine, Department of Infectious Diseases & Immunology, NYU Langone Medical Center, New York, NY, USA

DOI: https://doi.org/10.1016/j.idcr.2017.03.002
Journal volume & issue: Vol. 8, no. C
pp. 27 – 28

Abstract

Read online

The mainstay treatment of Clostridium difficile infections (CDI) is antimicrobials with growing support for fecal microbiota transplants. We report the first case of an elderly man with severe refractory NAP-1 pseudomembranous CDI who failed all medical therapy and two fecal transplants with response only seen after administration of intravenous immunoglobulin.

Published in IDCases

ISSN: 2214-2509 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Infectious and parasitic diseases
Website: http://www.journals.elsevier.com/idcases/

About the journal

Abstract

Keywords